Evidence map›Paper›PMID 36844628›Full record

ReviewOncology letters2023

Insulin‑like growth factor axis: A potential nanotherapy target for resistant cervical cancer tumors (Review).

Miguel Morales-Rodríguez, Lucero Paniagua-García, Jayanthi Narayanan, Horacio Zamudio-Meza, Ramón Víctor Moreno-Torres, Carlo César Cortés-González, José Antonio Juanico-Lorán, Beatriz Martínez-Pérez, Jorge Fernández-Retana

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Miguel Morales-RodríguezDirectorate of The Nanotechnology Engineering Division, Polytechnic University of The Valley of Mexico, Tultitlán, State of Mexico 54910, Mexico.
Lucero Paniagua-GarcíaDepartment of Biological Sciences, Section of Human Health Sciences, National Autonomous University of Mexico, Faculty of Advanced Studies Cuautitlán C1, Cuautitlán Izcalli, State of Mexico 54740, Mexico.
Jayanthi NarayananNanotechnology and Biotechnology Engineering Division, Polytechnic University of The Valley of Mexico, Tultitlán, State of Mexico 54910, Mexico.
Horacio Zamudio-MezaImmunochemistry Medical Research Unit, Specialty Hospital National Medical Center 'Siglo XXI' Mexican Social Security Institute, Mexico City 06720, Mexico.
Ramón Víctor Moreno-TorresMicrobial Ecology Laboratory, Unidad de Biotecnología y Prototipos-UBIPRO, National Autonomous University of Mexico, Faculty of Advanced Studies Iztacala Tlalnepantla de Baz, State of Mexico 54090, Mexico.
Carlo César Cortés-GonzálezBiomedical Unit for Cancer Research, Department of Basic Research, Biomedical Research Institute, National Autonomous University of Mexico/National Cancer Institute, Mexico City 14080, Mexico.
José Antonio Juanico-LoránNanotechnology and Biotechnology Engineering Division, Polytechnic University of The Valley of Mexico, Tultitlán, State of Mexico 54910, Mexico.
Beatriz Martínez-PérezNanotechnology and Biotechnology Engineering Division, Polytechnic University of The Valley of Mexico, Tultitlán, State of Mexico 54910, Mexico.
Jorge Fernández-RetanaNanotechnology and Biotechnology Engineering Division, Polytechnic University of The Valley of Mexico, Tultitlán, State of Mexico 54910, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is among the most frequently occurring neoplasms worldwide, and it particularly affects individuals in developing countries. Factors such as the low quality of screening tests, the high incidence of locally advanced cancer stages and the intrinsic resistance of certain tumors are the main causes of failure in the treatment of this neoplasm. Due to advances in the understanding of carcinogenic mechanisms and bioengineering research, advanced biological nanomaterials have been manufactured. The insulin-like growth factor (IGF) system comprises multiple growth factor receptors, including IGF receptor 1. These receptors are activated by binding to their respective growth factor ligands, IGF-1 and IGF-2, and insulin, and play an important role in the development, maintenance, progression, survival and treatment resistance of cervical cancer. In the present review, the role of the IGF system in cervical cancer and three nanotechnological applications that use elements of this system are described, namely Trap decoys, magnetic iron oxide nanoparticles and protein nanotubes. Their use in the treatment of resistant cervical cancer tumors is also discussed.

Indexed as

cervical cancer resistanceinsulin-like growth factor axisnanotherapytheranostic

Identifiers

PMID36844628
PMCPMC9950333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.